A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States

Abstract

With increased innovation and development of specialty pharmaceuticals, the US and global healthcare industries are looking to implement appropriate management strategies to control both utilization and costs. Specialty pharmaceuticals are high-cost medications that treat complex, chronic, rare, and difficult-to-manage conditions. These drugs require special drug handling, appropriate clinical outcomes monitoring, and effective cost controls. The primary scope of this article is to discuss various strategies being implemented for specialty pharmaceutical utilization and cost management and correlated outcomes in the USA; these outcomes include enhanced health insurance plan benefit designs with formulary modifications and greater patient cost burden. Additional methods to manage specialty pharmaceuticals include the use of specialty pharmacies for drug distribution, increased emphasis on coordination of care and evidence-based medicine, as well as healthcare reform and regulations. Healthcare spending, both in the US and globally, continues to increase, with a rising proportion of drug spend towards specialty pharmaceuticals. Continued specialty pharmaceutical innovation and introduction of biosimilar products will evolve the currently utilized management strategies for these drugs.

Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications

“…32 Although a few publications have examined specialty drug cost management strategies of health care payers, no consensus plan or method of action has been formulated. 33,34 Whether and how health care policies and innovative cost management strategies can help address the increasing cost challenges are important topics for future research. Some policymakers have suggested imposing a monthly OOP spending cap in Medicare Part D. The impact of such a policy change will greatly depend on the cap level.…”

The Role of the Diabetes Educator in Diabetes Formulary and Medical Device Decisions

“…3,4 Background Health insurance formularies have grown over time from simple medication lists to complex medication and medical device formularies with specialty "tiers" and shared cost burden. 5 Formulary composition and variations are also health system or company specific, creating greater complexity. In tiered formularies, medications are placed into categories, or tiers, based on lower-cost preferred drugs, higher-cost nonpreferred drugs, quantity restrictions, and copay amounts.…”

Update on biosimilars of granulocyte colony-stimulating factor – when no news is good news

“…Indeed, since the advent of biosimilars the price of first-generation G-CSF has dropped by as much as 80% [3,29,30,33], that is, much more than the 25-30% which had been predicted. The six or so biosimilar G-CSF products licensed in Europe together now outsell the originator [28,34]. Estimates were provided that additional competitors will exert additional pressure on G-CSF price [29], although at the current level this is hard to conceive.…”